Additionally, in TNBC and HER2-positive breast cancer, where a pathological complete response (pCR) was achieved with neoadjuvant chemotherapy, it has been reported that the disease-free survival (DFS) and overall survival (OS) rates were significantly improved compared to those in the group that did not achieve a pCR [2,4]. The gene discussed is ERBB2; the disease is breast cancer.